CUREator+ is a partnership between Brandon BioCatalyst and ANDHealth. Selected by the Federal Government’s Medical Research Future Fund (MRFF) through a competitive process, CUREator+ will deliver the $50 million MRFF BioMedTech Incubator (BMTI) program to medical research and medical innovation projects with commercial potential. CUREator+ brings together the experience of the Partners and their respective MRFF Early-Stage Translation and Commercialisation Support (ESTAC) programs, CUREator and ANDHealth+.
CUREator+ is a national program focused on accelerating the research translation and commercialisation of preclinical and clinical early-stage Australian medical research and medical innovations with commercial potential. These innovations include drugs (novel and repurposed), devices, diagnostics and digital technologies that address an unmet need, demonstrate a clear clinical and commercial differentiation, and are underpinned by strong intellectual property positions. It is expected that projects applying for CUREator+ funding possess a lead asset(s)/product/technology, which has demonstrated Proof of Concept/ Proof of Principle to support their funding request.
CUREator+ will provide small-to-medium enterprises (SMEs) with access to investment capital, commercial guidance, international expert networks, and hands-on support and mentorship to drive the translation and commercialisation of their opportunities. In addition to program oversight, SMEs will be supported to secure follow-on funding and facilitate their continued development.
CUREator+ will provide funding up to a maximum of $5 million per project in two funding stages.
Stage 1: Funding available between $1 million to $2.5 million. Funding will be provided in tranches and aligned to commercially relevant milestones. Successful projects will have up to 2 years to complete project activities and achievement of milestones, agreed as part of the application process.
Stage 2: Top-up funding will be available on a competitive basis to successful companies (maximum total of $5 million in grant funding per project from Stage 1 and 2) who meet their milestones during the Stage 1 period. Successful projects will have a maximum total of 4 years to complete Stage 1 and 2 project activities and achievement of milestones.
Funding round open
CUREator+ Funding will be available through a competitive process and delivered in two funding rounds.
The first round is now open for Expression of Interest (EOI) applications and will close on 6 October 2023 at 5pm AEDT. A second funding round will open in mid-2024.
Interested researchers and biotech companies are invited to apply via: https://cureatorplus.grantplatform.com/
Please refer to the funding guidelines and FAQs for further details available here.
For more information on CUREator+:
CUREator+ will host a national webinar and encourages provide prospective applicants to book a 30-minute meeting with the CUREator+ team to discuss their opportunity.
The webinar will be held on Wednesday 30th August at 12pm AEST. To register for the webinar visit: https://cureatorplus.grantplatform.com/ or https://andhealth-au.zoom.us/webinar/register/WN_vYBvpkBuQI6HTDBvPVc3gQ
To arrange a meeting to discuss any opportunities related to drugs, devices and diagnostics or general enquiries, please contact the CUREator team at: email@example.com
To arrange a meeting to discuss any opportunity related to digital and connected health innovations or general enquiries, please contact the ANDHealth team at firstname.lastname@example.org
You can download the FAQ’s and guidelines here.
You can watch the video of our recent webinar here.